Krebs Biochemicals & Industries Limited reported earnings results for the fourth quarter ended March 31, 2022. For the fourth quarter, the company reported sales was INR 178.05 million compared to INR 130.74 million a year ago. Revenue was INR 199.5 million compared to INR 163.03 million a year ago. Net loss was INR 113.14 million compared to INR 69.87 million a year ago. Basic loss per share from continuing operations was INR 5.39 compared to INR 3.47 a year ago. Diluted loss per share from continuing operations was INR 5.39 compared to INR 3.47 a year ago.